PDS Biotechnology (PDSB) investor relations material

Executive summary

• Strategic refocus in August 2026 prioritized PDS0301, a tumor-targeted IL-12 immunocytokine, as the lead program, discontinuing internal investment in PDS0101 and the VERSATILE-003 Phase 3 trial, and seeking partnerships for PDS0101 development.

• PDS0301 is in ongoing Phase 2 trials for multiple cancer indications, with published positive data in metastatic colorectal cancer showing higher objective response and survival rates compared to control.

• No commercial products or revenues; operations funded by equity and debt financings.

Financial highlights

• Net loss for Q2 2026 was $9.8 million ($0.18 per share), up from $9.4 million ($0.21 per share) in Q2 2025; six-month net loss was $17.1 million.

• Operating expenses for Q2 2026 decreased 15% year-over-year to $6.5 million, with R&D at $3.3 million (down 22%) and G&A at $3.2 million (down 5%).

• Cash and cash equivalents as of June 30, 2026 were $5.6 million, down from $26.7 million at year-end 2025.

• Accumulated deficit reached $233.7 million; total stockholders' equity was negative $3.6 million.

• Net interest expenses rose to $3.3 million from $1.8 million, driven by a non-cash charge for loss on retirement of debt.

Outlook and guidance

• Substantial doubt exists about the ability to continue as a going concern for at least 12 months due to limited cash and ongoing losses.

• Plans to fund operations through additional equity, debt, or strategic partnerships; no assurance of success.

• Focused on advancing PDS0301 in solid tumor indications where its mechanism may complement existing therapies and address treatment resistance.

• R&D expenses expected to increase as PDS0301 advances into further clinical trials.

• Intends to pursue strategic partnerships or external funding for PDS0101 development.